Recursion Announces Positive Clinical Data for REC-4881 and REC-1245, and Sanofi Partnership Milestone

Recursion reported updated Phase 1b/2 data for REC-4881 in Familial Adenomatous Polyposis, showing significant polyp burden reductions. Promising early Phase 1 data for REC-1245 in solid tumors, including confirmed partial responses in endometrial cancer, were also announced. Additionally, Sanofi has optioned a development candidate from their collaboration for inflammatory disease.